StimulusBio enables quantitative control of immune cell activation and expansion. Our patent-pending Programmable Cellular Interface (sbPCI™) technology presents stimulatory, co-stimulatory, and signaling molecules in a defined, tunable format, allowing researchers to precisely control signal presentation without genetic modification. The associated CellPilot™ product portfolio supports CAR-T, TIL, NK, CAR-NK, feeder cell replacement, and stem cell applications by providing a flexible, biocompatible platform for designing and optimizing cell therapies. We are currently offering early-access products and seeking additional collaborators.
Looking for a particular Stimulus Bio employee's phone or email?
Mimi Healy is the CEO of Stimulus Bio.
9 people are employed at Stimulus Bio.
Stimulus Bio is based in Houston, Texas.